Saturday 17 October 2026
Export GDTC’s income statement to Excel — free account
CytoMed Therapeutics Limited
GDTC Healthcare Biotechnology
CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024. Insiders bought in the last twelve months.
0.88
0.01
+1.15%
Follow GDTC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 2.36 | 1.20 | 1.29 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 9.25 | 4.90 | 4.05 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 28 | 34 | 43 | 42 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | (1) | (1) | (2) | (3) | (2) | (3) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (3,626.52) | (1,231.79) | |||||
| Net income | — | — | — | — | (1) | (2) | (2) | (3) | (2) | (3) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | ||||
| Earnings | — | — | — | — | 0.00 | 0.00 | (0.30) | (0.29) | (0.16) | (0.27) | |||||
| Cash flow | — | — | — | — | 0.00 | 0.00 | (0.13) | (0.24) | (0.17) | (0.25) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.04) | 0.00 | (0.09) | (0.05) | |||||
| Free cash flow | — | — | — | — | 0.00 | 0.00 | (0.18) | (0.25) | (0.27) | (0.29) | |||||
| Book value | — | — | — | — | 0.00 | 0.00 | 0.06 | 0.80 | 0.57 | 0.46 | |||||
| Shares, m | — | — | — | — | 2,246 | 2,642 | 8 | 11 | 12 | 12 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | 1,394.17 | 682.30 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (1,091.57) | (395.63) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (1) | (1) | (1) | (3) | (2) | (3) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | (1) | |||||
| Free cash flow | — | — | — | — | (1) | (1) | (1) | (3) | (3) | (3) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (1) | 0 | (1) | 7 | 4 | 2 | ||||
| Total debt | — | — | — | — | 2 | 2 | 3 | 0 | 0 | 0 | |||||
| Net debt | — | — | — | — | 2 | 1 | 2 | (6) | (3) | (1) | |||||
| Shareholders’ equity | — | — | — | — | 0 | 2 | 0 | 9 | 7 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (41.27) | (55.54) | (47.20) | (22.00) | (45.59) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (48.09) | (42.67) | (20.94) | (27.51) | |||||
| ROE | — | — | — | — | 0.00 | (133.76) | (197.96) | (69.92) | (24.33) | (51.81) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · fundamentals updated 2 Oct 2026
Charts ten years each
CytoMed Therapeutics Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals Corp. | $10.8M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $10.7M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $10.7M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GDTC CytoMed Therapeutics Limited | $10.3M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | |
| BLRX BioLineRx Ltd. | $10.2M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LTRN Lantern Pharma Inc. | $10.0M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TOVX Theriva Biologics, Inc. | $9.7M | 0.1× | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BIVI BioVie Inc. | $9.6M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $9.6M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $10.1M | — | — | −40.13% | — | +29.77% | 39.97% | 0.00% |
CytoMed Therapeutics Limited (GDTC) key facts
- Concern: CytoMed Therapeutics Limited reported a net loss of $3.1 million, or a loss of $0.27 per share, for fiscal 2025.
- Strength: CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024.
- CytoMed Therapeutics Limited (GDTC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GDTC traded at $0.88, a market capitalization of $10.3 million.
- Return on equity was −51.8% and debt-to-equity 0.08.
- Its Altman Z-score is 6.84 (safe zone) for fiscal 2025.
CytoMed Therapeutics Limited (GDTC) Latest News
No news at this impact. Lower the threshold for more.